Boston, September 17, 2025
News Summary
NanoViricides, Inc. will showcase its latest antiviral developments, including updates on their flagship candidate NV-387, at the LSX World Congress in Boston. Scheduled for September 17, the presentation, led by President Anil R. Diwan, will focus on the company’s drug pipeline and strategic licensing opportunities. Attendees can expect insights into NV-387’s clinical progress, targeting respiratory pathogens, as well as additional candidates in preclinical development. The event also serves as a networking platform for potential collaborators and partners in biotech.
Boston — NanoViricides, Inc. will present new antiviral developments at the LSX World Congress in Boston on Wednesday, September 17, 2025, with a scheduled presentation at 12:30 PM at the Thomas Michael Menino Convention and Exhibition Center. The company plans to update attendees on its drug pipeline and platform technologies available for licensing, and the presentation will be accompanied by multiple partnering meetings on September 16 and 17.
Key presentation and timing
The LSX World Congress presentation will be delivered by Anil R. Diwan, PhD, President and Executive Chairman of NanoViricides. The company has arranged partnering sessions during the conference dates to engage with potential collaborators and licensees. The LSX event runs September 16–17, 2025, with pre-conference forums on September 15 that bring together leaders across biotech, medtech, and pharmatech sectors for networking and collaboration.
Main focus: NV-387 and clinical progress
NanoViricides’ most advanced candidate, NV-387, is identified as an ultra-broad-spectrum antiviral targeting a wide range of respiratory pathogens. The drug is described as a chemical nanomachine that disrupts virus particles and prevents infections. NV-387 is designed to emulate sulfated proteoglycans, which serve as a binding site for an estimated >90% of human viruses, a feature that the company says makes it difficult for viruses to develop escape mutations.
Preclinical performance and targeted indications
According to the company’s material, NV-387 has shown effectiveness in animal models against concurrent respiratory pathogens often referenced as the “tripledemic”: Respiratory Syncytial Virus (RSV), Influenza A, and Coronaviruses. The candidate reportedly outpaced existing drugs in these animal studies and demonstrated high efficacy against RSV, including a complete cure in the cited animal study. NV-387 has also shown promise in animal models for Smallpox, MPox, and Measles.
Regulatory and clinical development status
NV-387 is advancing toward Phase II evaluation for safety, tolerability, and efficacy in treating MPox amid an ongoing public health emergency. The company reports preliminary approval of the clinical protocol for that indication. Successful treatment of MPox could make NV-387 eligible for a Priority Review Voucher (PRV) from the U.S. Food and Drug Administration, which the company estimates could be valued between $150 million and $350 million.
Market opportunity and strategic positioning
With no currently approved treatments for RSV, MPox, or Measles, NanoViricides positions NV-387 as a potential cornerstone for empiric antiviral therapy that can be used at the point of diagnosis without immediate virus identification. The company estimates the combined market for indications associated with NV-387 exceeds $10 billion. NanoViricides is also promoting its platform technologies and licensing opportunities to potential partners at the LSX Congress.
Pipeline beyond NV-387
In addition to NV-387, NanoViricides lists other candidates in preclinical development: NV-HHV-1, described as a pan-herpesvirus drug candidate, and NV-HIV-1, an anti-HIV candidate that has shown strong efficacy in animal models. The company also notes an ongoing relationship with TheraCour Pharma, which provides a foundation for continued antiviral research and development.
Event context and networking
The LSX World Congress is scheduled to include industry forums, partnering sessions, and presentations over two days. NanoViricides’ scheduled presentation and meetings are positioned to inform potential collaborators, investors, and licensing partners about the company’s technology platform and clinical plans.
Background
The LSX World Congress convenes leaders from the life sciences, biotech, and pharmaceutical sectors to discuss partnering, deal-making, and innovation. Presentations at the conference typically cover pipeline updates, platform technologies, and licensing opportunities for emerging therapies. NanoViricides’ announcement aligns with the event’s focus on connecting companies advancing clinical-stage and platform technologies with potential partners.
FAQ
What is being presented at the LSX World Congress?
NanoViricides will present updates on its antiviral pipeline and platform technologies, with a focus on its lead candidate, NV-387. The presentation is scheduled for September 17, 2025, at 12:30 PM.
Where and when is the event?
The LSX World Congress is taking place at the Thomas Michael Menino Convention and Exhibition Center in Boston, Massachusetts. The conference dates are September 16–17, 2025, with related forums on September 15.
What is NV-387 and how does it work?
NV-387 is described as an ultra-broad-spectrum antiviral chemical nanomachine that disrupts virus particles. It is engineered to emulate sulfated proteoglycans, a common viral binding site, to reduce the likelihood of viral escape.
What is the clinical status of NV-387?
NV-387 is progressing toward Phase II evaluation for MPox treatment, with preliminary approval of a clinical protocol reported. Preclinical studies in animals have shown efficacy against RSV, Influenza A, Coronaviruses, Smallpox, MPox, and Measles.
Could NV-387 receive a Priority Review Voucher?
Successful treatment of MPox could make NV-387 eligible for a U.S. FDA Priority Review Voucher, which the company estimates may be valued between $150 million and $350 million.
What other candidates are in the NanoViricides pipeline?
Other candidates include NV-HHV-1, a pan-herpesvirus candidate, and NV-HIV-1, an anti-HIV candidate that has shown strong efficacy in animal models.
Event and program at-a-glance
| Item | Details |
|---|---|
| Presenter | Anil R. Diwan, PhD — President and Executive Chairman, NanoViricides |
| Presentation Date & Time | Wednesday, September 17, 2025 — 12:30 PM |
| Event | LSX World Congress (including partnering sessions) |
| Venue | Thomas Michael Menino Convention and Exhibition Center, Boston, MA |
| Main drug candidate | NV-387 — ultra-broad-spectrum antiviral |
| Clinical milestone | Toward Phase II evaluation for MPox; preliminary protocol approval reported |
| Notable preclinical results | Efficacy in animal models for RSV, Influenza A, Coronaviruses, Smallpox, MPox, and Measles |
| Other pipeline candidates | NV-HHV-1 (pan-herpesvirus), NV-HIV-1 (anti-HIV) |
| Estimated market opportunity | Exceeds $10 billion for associated indications |
| Potential regulatory benefit | Priority Review Voucher potential valued at $150M–$350M if MPox indication is successful |
Deeper Dive: News & Info About This Topic
HERE Resources
NanoViricides to Present Antiviral Drug Developments in Boston
Additional Resources
- NanoViricides at LSX Congress – JSONline
- NanoViricides Presentation – Proactive Investors
- Wikipedia: Nanotechnology
- Google Search: NanoViricides
- Encyclopedia Britannica: Nanotechnology
Author: STAFF HERE BOSTON WRITER
BOSTON STAFF WRITER The BOSTON STAFF WRITER represents the experienced team at HEREBoston.com, your go-to source for actionable local news and information in Boston, Suffolk County, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as Boston Marathon, Head of the Charles Regatta, and Boston Harborfest. Our coverage extends to key organizations like the Greater Boston Chamber of Commerce and Associated Industries of Massachusetts, plus leading businesses in finance, biotech, and insurance that power the local economy such as Fidelity Investments, Biogen, and Liberty Mutual Insurance. As part of the broader HERE network, we provide comprehensive, credible insights into Massachusetts's dynamic landscape.
